|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000133321 |
Summary for RARRES3 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000133321 | Gene symbol | RARRES3 |
| Gene name | phospholipase A and acyltransferase 4 | |
| HGNC | 9869 | |
| Entrez ID | 5920 | |
| Gene type | protein_coding | |
| Synonyms | PLAAT4|TIG3|HRASLS4|PLAAT-4|RIG1 | |
| UniProtAcc | Q9UL19 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for RARRES3 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| RARRES3 | 1.95e+03 | -1.54e+00 | 2.13e-01 | -7.21e+00 | 5.43e-13 | 1.68e-12 | LUSC |
| RARRES3 | 3.09e+03 | 1.45e+00 | 5.96e-01 | 2.43e+00 | 1.51e-02 | 3.39e-02 | BLCA |
| RARRES3 | 4.42e+03 | 1.22e+00 | 2.12e-01 | 5.76e+00 | 8.41e-09 | 4.16e-08 | KIRP |
| RARRES3 | 1.66e+03 | -1.27e+00 | 5.25e-01 | -2.42e+00 | 1.54e-02 | 3.58e-02 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| RARRES3 | 7.18e+03 | 1.37e+00 | 1.34e-01 | 1.03e+01 | 1.09e-24 | 4.51e-24 | BRCA |
Top |
Sex-biased somatic mutation for RARRES3 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for RARRES3 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg04999352 | chr11:63537142 | CGI:chr11:63490906-63491332 | promoter,gene body | 2.61e-01 | 4.36e-01 | -2.47e+00 | 1.34e-02 | 2.98e-02 | -1.74e-01 |
| LIHC | cg05817709 | chr11:63536626 | CGI:chr11:63490906-63491332 | promoter | 4.12e-01 | 2.84e-01 | 2.13e+00 | 3.29e-02 | 3.84e-02 | 1.28e-01 |
| ACC | cg18112681 | chr11:63535927 | CGI:chr11:63490906-63491332 | promoter | 6.05e-01 | 7.20e-01 | -2.12e+00 | 3.41e-02 | 4.34e-02 | -1.14e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg05817709 | chr11:63536626 | CGI:chr11:63490906-63491332 | promoter | 4.84e-01 | 6.77e-01 | -2.52e+00 | 1.16e-02 | 1.55e-02 | -1.93e-01 |
| LUSC | cg04999352 | chr11:63537142 | CGI:chr11:63490906-63491332 | promoter,gene body | 4.49e-01 | 2.36e-01 | 2.49e+00 | 1.27e-02 | 1.67e-02 | 2.13e-01 |
| COAD | cg04999352 | chr11:63537142 | CGI:chr11:63490906-63491332 | promoter,gene body | 2.84e-01 | 5.07e-01 | -3.65e+00 | 2.60e-04 | 7.55e-04 | -2.24e-01 |
| BLCA | cg18112681 | chr11:63535927 | CGI:chr11:63490906-63491332 | promoter | 6.78e-01 | 8.02e-01 | -2.19e+00 | 2.86e-02 | 3.24e-02 | -1.24e-01 |
| BLCA | cg05817709 | chr11:63536626 | CGI:chr11:63490906-63491332 | promoter | 4.76e-01 | 7.24e-01 | -2.97e+00 | 2.93e-03 | 5.32e-03 | -2.47e-01 |
| LIHC | cg05817709 | chr11:63536626 | CGI:chr11:63490906-63491332 | promoter | 2.84e-01 | 3.87e-01 | -2.18e+00 | 2.92e-02 | 3.12e-02 | -1.03e-01 |
| ESCA | cg05817709 | chr11:63536626 | CGI:chr11:63490906-63491332 | promoter | 3.87e-01 | 5.82e-01 | -2.13e+00 | 3.28e-02 | 4.47e-02 | -1.94e-01 |
| CHOL | cg04999352 | chr11:63537142 | CGI:chr11:63490906-63491332 | promoter,gene body | 3.12e-01 | 9.04e-02 | 3.02e+00 | 2.51e-03 | 1.19e-02 | 2.21e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg05817709 | chr11:63536626 | CGI:chr11:63490906-63491332 | promoter | 4.53e-01 | 5.99e-01 | -6.21e+00 | 5.31e-10 | 1.32e-09 | -1.47e-01 |
| LUAD | cg18112681 | chr11:63535927 | CGI:chr11:63490906-63491332 | promoter | 6.48e-01 | 7.97e-01 | -3.13e+00 | 1.74e-03 | 4.64e-03 | -1.49e-01 |
Top |
Exon skipping events with PSI in TCGA for RARRES3 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for RARRES3 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for RARRES3 |
| TFs related to RARRES3. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | PLAGL2 | RARRES3 | 2.54e+00 | 5.78e-04 | 4.65e+00 | 9.92e-01 | Female-biased |
| BRCA | ZNF19 | RARRES3 | 2.70e+00 | 3.22e-03 | 4.27e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF479 | RARRES3 | 2.87e+00 | 3.46e-03 | 4.41e+00 | 9.85e-01 | Female-biased |
| BRCA | ZNF707 | RARRES3 | 2.61e+00 | 2.49e-03 | 4.25e+00 | 9.82e-01 | Female-biased |
| GBM | ESR1 | RARRES3 | 3.13e+00 | 8.86e-03 | 4.22e+00 | 9.81e-01 | Female-biased |
| GBM | ZNF552 | RARRES3 | 2.88e+00 | 5.17e-03 | 4.19e+00 | 9.85e-01 | Female-biased |
| GBM | ZNF708 | RARRES3 | 2.62e+00 | 3.95e-03 | 4.02e+00 | 9.82e-01 | Female-biased |
| RARRES3 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for RARRES3 |
| RBPs related to ES in RARRES3. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | RBMS1 | exon_skip_60277 | 1.21e+01 | 1.16e-02 | 1.24e+01 | 9.88e-01 | Female-biased |
| BRCA | RBMS1 | exon_skip_60277 | 1.17e+01 | 9.95e-01 | 1.10e+01 | 4.45e-03 | Male-biased |
| KICH | RBMS1 | exon_skip_60277 | 1.17e+01 | 7.39e-03 | 1.21e+01 | 9.92e-01 | Female-biased |
| RARRES3 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs78176556 | chr11:66522772:T:C | - | 0.263972223031684 | 3.03204141724928e-08 | LUSC | Female-baised eQTL |
| rs375498560 | chr11:66619724:A:G | - | 0.192917610661527 | 4.48821555764035e-05 | LUSC | Female-baised eQTL |
| rs184831536 | chr11:66619728:A:G | - | 0.192917610661527 | 4.48821555764035e-05 | LUSC | Female-baised eQTL |
| rs374336308 | chr11:66619739:T:A | - | 0.192917610661527 | 4.48821555764035e-05 | LUSC | Female-baised eQTL |
| rs75434281 | chr11:66922335:G:A | - | 0.191853240895608 | 5.57761056767841e-05 | LUSC | Female-baised eQTL |
| rs188249723 | chr11:66629246:C:T | - | 0.167083483927247 | 0.000700920386310177 | LUSC | Female-baised eQTL |
| rs76693359 | chr11:66882126:T:G | - | 0.145709283178534 | 0.00309025107499405 | LUSC | Female-baised eQTL |
| rs74788170 | chr11:66810462:A:G | - | 0.145638879827876 | 0.00311356012523103 | LUSC | Female-baised eQTL |
| rs78094475 | chr11:66684037:G:A | - | 0.145566055839922 | 0.00314001623383158 | LUSC | Female-baised eQTL |
| rs77589052 | chr11:66684089:C:T | - | 0.145566055839922 | 0.00314001623383158 | LUSC | Female-baised eQTL |
| rs61886409 | chr11:70685611:G:A | - | 0.20326282825615 | 0.00870833875965624 | LUSC | Female-baised eQTL |
| rs61886718 | chr11:57029871:C:T | - | 0.100394567141854 | 0.028256280226989 | LUSC | Female-baised eQTL |
| rs2000516 | chr11:70688167:G:A | - | 0.186924320569738 | 0.0327192687680557 | LUSC | Female-baised eQTL |
| rs61886717 | chr11:57004982:C:G | - | 0.0958066472587103 | 0.0431951272330726 | LUSC | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs10737161 | chr11:69383930:A:G | - | -0.0880742890594758 | 0.0133606872837485 | LIHC | Male-baised eQTL |
| rs7484184 | chr11:69383521:A:G | - | -0.0863656380661696 | 0.0137209902327391 | LIHC | Male-baised eQTL |
| rs66721208 | chr11:69382682:T:C | - | -0.0846928368916873 | 0.0181052962513648 | LIHC | Male-baised eQTL |
| rs4980737 | chr11:69382224:A:G | - | -0.0845017674412109 | 0.0187240870227732 | LIHC | Male-baised eQTL |
| rs17704641 | chr11:61415916:C:T | - | 0.0639285256286182 | 0.0280256168199456 | LGG | Male-baised eQTL |
| rs3741370 | chr11:66222287:G:T | - | 0.0598132505643412 | 0.0329590589830473 | LGG | Male-baised eQTL |
| rs3782081 | chr11:66231461:C:T | - | 0.0598132505643412 | 0.0329590589830473 | LGG | Male-baised eQTL |
| rs61891385 | chr11:66271304:A:T | - | 0.0598132505643412 | 0.0329590589830473 | LGG | Male-baised eQTL |
| rs2282567 | chr11:66285164:C:A | - | 0.0598132505643412 | 0.0329590589830473 | LGG | Male-baised eQTL |
| rs57579741 | chr11:66285165:C:T | - | 0.0598132505643412 | 0.0329590589830473 | LGG | Male-baised eQTL |
| rs11238042 | chr11:70942895:G:A | - | 0.0468450875000419 | 0.0358549841438621 | LGG | Male-baised eQTL |
| rs7101450 | chr11:70949160:T:C | - | 0.0439918236498016 | 0.0413619040493123 | LGG | Male-baised eQTL |
| rs3862387 | chr11:66172450:T:G | - | 0.0573273817525825 | 0.0465395577089007 | LGG | Male-baised eQTL |
| rs12420458 | chr11:66175310:G:C | - | 0.0573273817525825 | 0.0465395577089007 | LGG | Male-baised eQTL |
| rs61890290 | chr11:66178899:T:C | - | 0.0573273817525825 | 0.0465395577089007 | LGG | Male-baised eQTL |
| rs11231653 | chr11:63948432:A:G | - | -0.0404199530698513 | 0.0116177320696242 | KIRC | Male-baised eQTL |
| rs481835 | chr11:63958310:C:T | - | -0.0402676291841561 | 0.0130872320200227 | KIRC | Male-baised eQTL |
| rs7928990 | chr11:63964126:C:T | - | 0.0400082043243784 | 0.014305543376032 | KIRC | Male-baised eQTL |
| rs10897466 | chr11:63955766:A:G | - | 0.0379965773638739 | 0.027777427417731 | KIRC | Male-baised eQTL |
| rs11601228 | chr11:63962838:A:G | - | 0.0375268984402885 | 0.0320564615313003 | KIRC | Male-baised eQTL |
| rs12420866 | chr11:63228778:A:G | - | 0.052906141932187 | 0.0383889398308579 | BLCA | Male-baised eQTL |
| rs12283313 | chr11:64006829:C:T | - | 0.0991593084949898 | 0.0135520239666102 | LUAD | Male-baised eQTL |
| rs558660 | chr11:59836421:A:G | - | -0.0468977876445492 | 0.040666773478549 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000133321 |
| CpG Site: cg18112681 | |
| Position to Gene: promoter | |
| Male Effect: -0.449693508584889 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg18112681 | chr11:63535927 | promoter | -0.449693508584889 | 3.57025343505415e-16 | -0.5573002905972525 | 1.3525676687121092e-19 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of RARRES3 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
